文献速递中医妇科中药与中成药合理使用

生化汤辅助早期药物流产疗效的Meta分析

The efficacy of Shenghua Decoction supplementation after early medical abortion: A meta-analysis of randomized controlled trials.
PubMed 文献 · Complement Ther Med · 2022-06-30

本研究通过Meta分析评估生化汤辅助米非司酮序贯米索前列醇早期药物流产的疗效,纳入16项RCT共3016例患者。结果显示生化汤可提高完全流产率、降低不全流产率及活胎率,并缩短引产至流产时间、阴道出血时间和月经恢复时间,但纳入研究方法学质量欠佳,需进一步验证。

要点

  • 生化汤辅助早期药物流产可提高完全流产率(RR=1.14)。
  • 生化汤可降低不全流产率(RR=0.31)和活胎率(RR=0.26)。
  • 生化汤可缩短阴道出血时间和月经恢复时间。

核心结论

  • 生化汤辅助可能对妊娠7周内选择药物流产的女性有益,且实验组未报告不良事件。
  • 纳入RCT的方法学质量不令人满意,需严格设计的标准化研究进一步验证。

研究设计与样本

  • 系统综述与Meta分析,遵循2020 PRISMA指南,检索8个数据库至2022年2月28日,纳入16项RCT共3016例患者。
  • 采用GRADE评估证据质量。

主要发现

  • 与无治疗对照组相比,生化汤组完全流产率更高(RR: 1.14; 95% CI: 1.10-1.18; P<0.01, I2=26%,中等质量)。
  • 生化汤组不全流产率更低(RR: 0.31; 95% CI: 0.24-0.41; P<0.01, I2=0%,中等质量)。
  • 生化汤组活胎率更低(RR: 0.26; 95% CI: 0.11-0.62; P<0.01, I2=0%,中等质量)。
  • 生化汤辅助与引产至流产时间、阴道出血持续时间及月经恢复时间缩短相关。

关键数值与推荐

  • 完全流产率RR: 1.14; 95% CI: 1.10-1.18; P<0.01, I2=26%,中等质量。
  • 不全流产率RR: 0.31; 95% CI: 0.24-0.41; P<0.01, I2=0%,中等质量。
  • 活胎率RR: 0.26; 95% CI: 0.11-0.62; P<0.01, I2=0%,中等质量。

临床怎么用

  • 对于妊娠7周内选择药物流产的女性,可考虑在米非司酮序贯米索前列醇方案基础上加用生化汤辅助治疗。
  • 临床应用时应结合患者意愿和具体情况,并注意现有证据方法学质量有限。

局限性

  • 纳入RCT的方法学质量不令人满意。
  • 证据质量经GRADE评估为中等质量,需标准化严格设计研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Shenghua Decoction (SHD) is a well-known classic herbal formula documented in traditional Chinese medicine (TCM) that has been widely applied during the postpartum period in Chinese communities for several years. We conducted this systematic review and meta-analysis to explore the influence of SHD as an adjuvant treatment for early medical abortion using a combination of mifepristone followed by misoprostol. METHODS: This systematic review and meta-analysis was reported using 2020 PRISMA guidelines. Eight databases were searched from their establishment to February 28, 2022, for randomized controlled trials (RCTs): PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, the Chinese BioMedical database, the Chinese Scientific Journal Database, and the Wanfang database. The Grading of Recommendations Assessment, Development, and Evaluation estimated the quality of evidence. RESULTS: Sixteen RCTs involving 3016 patients were included in the meta-analysis. Overall, compared with no treatment as the control group after early medical abortion, patients treated with SHD were associated with a higher complete abortion rate (RR: 1.14; 95% CI: 1.10 - 1.18; P < 0.01, I2 = 26%, moderate quality), lower incomplete abortion rate (RR: 0.31; 95% CI: 0.24 - 0.41; P < 0.01, I2 = 0%, moderate quality), and lower viable pregnancy rate (RR: 0.26; 95% CI: 0.11 - 0.62; P < 0.01, I2 = 0%, moderate quality). Additionally, SHD supplementation was associated with reduced the induction-abortion time, duration of vaginal bleeding and menstrual recovery time. CONCLUSION: Our findings suggest that SHD supplementation may be beneficial for women seeking a medical abortion before the 7-week gestational period and no adverse events in the experimental group were reported. However, the methodological quality of the included RCTs was unsatisfactory, and therefore it is necessary to further verify the effectiveness of SHD using standardized studies of rigorous design.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Li HF, Chen WM, Shen HL, et al. The efficacy of Shenghua Decoction supplementation after early medical abortion: A meta-analysis of randomized controlled trials. Complement Ther Med. 2022. PMID: 35779783. doi:10.1016/j.ctim.2022.102848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。